Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study

Ahmed Bagit; Khalad Maliyar; Mark Mansour; Jorge R Georgakopoulos; Brian Rankin; Yuliya Lytvyn; Hiba Zaaroura; Ye-Jean Park; Emilie Wang; Asfandyar Mufti; Tiago Torres; Ana M Le; Ronald Vender; Vimal H Prajapati; Jensen Yeung

doi:10.1016/j.jaad.2024.03.048

Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study

J Am Acad Dermatol. 2024 Sep;91(3):513-515. doi: 10.1016/j.jaad.2024.03.048. Epub 2024 Apr 25.

Authors

Affiliations

¹ Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
² Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
³ Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
⁴ Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁵ Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
⁶ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
⁷ Department of Dermatology, Centro Hospitalar de Santo António, Porto, Portugal; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.
⁸ Department of Dermatology, Centro Hospitalar de Santo António, Porto, Portugal.
⁹ Dermatrials Research Inc. and Venderm Consulting, Hamilton, Ontario, Canada.
¹⁰ Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Dermatology Research Institute, Calgary, Alberta, Canada; Probity Medical Research, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Section of Community Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
¹¹ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada; Probity Medical Research, Toronto, Ontario, Canada. Electronic address: [email protected].

PMID: 38677338
DOI: 10.1016/j.jaad.2024.03.048

No abstract available

Keywords: IL-23 inhibitor; biologic; efficacy; psoriasis; real-world; risankizumab; safety.

Publication types

Multicenter Study

MeSH terms

Adult
Aged
Antibodies, Monoclonal* / adverse effects
Antibodies, Monoclonal* / therapeutic use
Dermatologic Agents / adverse effects
Dermatologic Agents / therapeutic use
Female
Humans
Male
Middle Aged
Psoriasis* / drug therapy
Retrospective Studies
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal
Dermatologic Agents
risankizumab